E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/3/2006 in the Prospect News Biotech Daily.

S&P affirms Beckman Coulter

Standard & Poor's said it affirmed its ratings on Beckman Coulter Inc., including the BBB corporate credit rating.

The affirmation follows the company's agreement to purchase privately held Lumigen Inc. in a $185 million all-cash transaction, the agency said.

The outlook is negative.

Although S&P said it expects that the initial borrowings needed to fund this acquisition will represent a permanent addition to the company's existing debt level, the expected operating improvements to be gained by this vertical integration will largely offset the increase in debt.

The ratings on Beckman Coulter reflect the company's satisfactory business risk profile based on its leading positions in an attractive market characterized by substantial recurring revenue streams and an intermediate financial risk profile, the agency noted.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.